Telomir Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	Current	Dec 31, 2023
Market Capitalization	115	-
Enterprise Value	108	0
PB Ratio	36.81	-
EV/EBITDA Ratio	-	-0.01
EV/EBIT Ratio	-	-0.01
EV/FCF Ratio	-	-0.03
Debt / Equity Ratio	-	0.03
Debt / EBITDA Ratio	-	-0.01
Debt / FCF Ratio	-	-0.03
Quick Ratio	7.00	0.10
Current Ratio	7.20	0.33
Interest Coverage	-	-6.96
Return on Equity (ROE)	-	-1045.40%
Return on Assets (ROA)	-	-542.10%
Return on Capital (ROIC)	-	-111.38%
Earnings Yield	-16.97%	-
Buyback Yield / Dilution	-3.50%	-8.16%
Total Shareholder Return	-3.50%	-8.16%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).